These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 20933070

  • 1. Inorganic-polymer nanohybrid carrier for delivery of a poorly-soluble drug, ursodeoxycholic acid.
    Choi G, Lee JH, Oh YJ, Choy YB, Park MC, Chang HC, Choy JH.
    Int J Pharm; 2010 Dec 15; 402(1-2):117-22. PubMed ID: 20933070
    [Abstract] [Full Text] [Related]

  • 2. Drug-inorganic-polymer nanohybrid for transdermal delivery.
    Kim MH, Park DH, Yang JH, Choy YB, Choy JH.
    Int J Pharm; 2013 Feb 28; 444(1-2):120-7. PubMed ID: 23357253
    [Abstract] [Full Text] [Related]

  • 3. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
    Maghsoodi M, Sadeghpoor F.
    Drug Dev Ind Pharm; 2010 Aug 28; 36(8):917-25. PubMed ID: 20180658
    [Abstract] [Full Text] [Related]

  • 4. In-vitro release kinetics and stability of anticardiovascular drugs-intercalated layered double hydroxide nanohybrids.
    Panda HS, Srivastava R, Bahadur D.
    J Phys Chem B; 2009 Nov 12; 113(45):15090-100. PubMed ID: 19831399
    [Abstract] [Full Text] [Related]

  • 5. Controlled release of donepezil intercalated in smectite clays.
    Park JK, Choy YB, Oh JM, Kim JY, Hwang SJ, Choy JH.
    Int J Pharm; 2008 Jul 09; 359(1-2):198-204. PubMed ID: 18502063
    [Abstract] [Full Text] [Related]

  • 6. Enteric-coated layered double hydroxides as a controlled release drug delivery system.
    Li B, He J, Evans DG, Duan X.
    Int J Pharm; 2004 Dec 09; 287(1-2):89-95. PubMed ID: 15541916
    [Abstract] [Full Text] [Related]

  • 7. [Characteristics of a new controlled release formulation of ursodesoxycholic acid].
    Carli F, Brambilla A, Di Rella M, Frattini C, Brandt A.
    Boll Chim Farm; 1996 Jan 09; 135(1):12-4. PubMed ID: 9004735
    [Abstract] [Full Text] [Related]

  • 8. Improvement of oxaprozin solubility and permeability by the combined use of cyclodextrin, chitosan, and bile components.
    Maestrelli F, Cirri M, Mennini N, Zerrouk N, Mura P.
    Eur J Pharm Biopharm; 2011 Aug 09; 78(3):385-93. PubMed ID: 21439375
    [Abstract] [Full Text] [Related]

  • 9. Inorganic layered double hydroxides as ascorbic acid (vitamin C) delivery system--intercalation and their controlled release properties.
    Gasser MS.
    Colloids Surf B Biointerfaces; 2009 Oct 01; 73(1):103-9. PubMed ID: 19502014
    [Abstract] [Full Text] [Related]

  • 10. Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs.
    Wu C, Wang Z, Zhi Z, Jiang T, Zhang J, Wang S.
    Int J Pharm; 2011 Jan 17; 403(1-2):162-9. PubMed ID: 20937370
    [Abstract] [Full Text] [Related]

  • 11. Dissolution kinetics and mechanism of Mg-Al layered double hydroxides: a simple approach to describe drug release in acid media.
    Parello ML, Rojas R, Giacomelli CE.
    J Colloid Interface Sci; 2010 Nov 01; 351(1):134-9. PubMed ID: 20709325
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
    Zahedi P, Lee PI.
    Eur J Pharm Biopharm; 2007 Mar 01; 65(3):320-8. PubMed ID: 17182231
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and characterization of arsenate-intercalated layered double hydroxides (LDHs): prospects for arsenic mineralization.
    Prasanna SV, Kamath PV.
    J Colloid Interface Sci; 2009 Mar 15; 331(2):439-45. PubMed ID: 19135682
    [Abstract] [Full Text] [Related]

  • 16. Removal of chloride ion from aqueous solution by ZnAl-NO(3) layered double hydroxides as anion-exchanger.
    Lv L, Sun P, Gu Z, Du H, Pang X, Tao X, Xu R, Xu L.
    J Hazard Mater; 2009 Jan 30; 161(2-3):1444-9. PubMed ID: 18571847
    [Abstract] [Full Text] [Related]

  • 17. Pharmaceutical suspensions of ursodeoxycholic acid for pediatric patients: in vitro and in vivo studies.
    Boscolo O, Salvo L, Dobrecky C, Fissore EN, Buontempo F, Tripodi V, Lucangioli SE.
    Pharm Dev Technol; 2021 Jun 30; 26(5):599-609. PubMed ID: 33759695
    [Abstract] [Full Text] [Related]

  • 18. Intercalation of hydrophilic and hydrophobic antibiotics in layered double hydroxides.
    Trikeriotis M, Ghanotakis DF.
    Int J Pharm; 2007 Mar 06; 332(1-2):176-84. PubMed ID: 17070662
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of amorphous ursodeoxycholic acid by thermal methods.
    Yonemochi E, Ueno Y, Ohmae T, Oguchi T, Nakajima S, Yamamoto K.
    Pharm Res; 1997 Jun 06; 14(6):798-803. PubMed ID: 9210200
    [Abstract] [Full Text] [Related]

  • 20. Bioavailability of a controlled release formulation of ursodeoxycholic acid in man.
    Alvisi V, Gasparetto A, Dentale A, Heras H, Felletti-Spadazzi A, D'Ambrosi A.
    Drugs Exp Clin Res; 1996 Jun 06; 22(1):29-33. PubMed ID: 8839635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.